Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.
Adaptative immune response mediated by NKG2D receptor and its ligand NKG2DL could be the clue for CD8-expressing “killer” T cells to kill tumors lacking the major histocompatibility complex (MHC) ...
Enhanced Signal-to-Noise Ratio as a Primary Advantage of MBLI Tetramers Concerning Biological Interactions with Dextran. In this blog, we will discuss the increasing evidence in the literature and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results